Drugs / OC-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04260802 | Sep 2020 → Nov 2025 | cervical cancer, cutaneous neuroendocrine carcinoma, gastric cancer, head and neck squamous cell carcinoma +9 | Ocellaris Pharma, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OC-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04260802 ↗ |
| Route | Intravenous | “Administered IV.” NCT04260802 ↗ |